Dyne Therapeutics logo
Dyne Therapeutics
DYN | NASDAQ
Chart Builder DCF Calculator
$16.70
-$0.46 (-2.68%)
At close: Nov 16, 2026, 4:00 PM ET
$16.75
+$0.05 (+0.30%)
After-hours: Nov 16, 2026, 7:30 PM ET

Dyne Therapeutics Company Profile

Company profile explained

Company Profile

Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, in addition to other rare skeletal, cardiac, and metabolic muscle diseases. The company was founded in 2017 and maintains its corporate headquarters in Waltham, Massachusetts.

Key Executives

Name Position
John G. Cox Chief Executive Officer, President & Director
Alessandro Martuscelli Chief Legal Officer
Erick J. Lucera Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer and Treasurer
Axel Wiest Senior VP and Head of Portfolio Strategy & Operations
Douglas Kerr Chief Medical Officer
James Bilotta Chief Digital & Information Officer
Johanna Friedl-Naderer Chief Commercial Officer
Lucia Celona Chief Human Resource Officer
Oxana Beskrovnaya Chief Innovation Officer
Rajesh Manchanda Chief Technical Officer

Latest SEC Filings

Date Type Title
Oct 22, 2026 4 Filing
Oct 06, 2026 4 Filing
Sep 29, 2026 8-K Current Report
Sep 08, 2026 4 Filing
Sep 08, 2026 4 Filing
Sep 08, 2026 4 Filing
Aug 17, 2026 4 Filing
Aug 17, 2026 4 Filing
Aug 17, 2026 4 Filing
Aug 17, 2026 4 Filing
View All SEC Filings ➞
Dyne Therapeutics
Dyne Therapeutics logo
Country United States
IPO Date Sep 17, 2020
Industry Biotechnology
Sector Healthcare
Employees 289
CEO John G. Cox

Contact Details

1560 Trapelo Road Waltham, Massachusetts 02451 United States

Stock Details

Ticker Symbol DYN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001818794
CUSIP Number 26818M108
ISIN Number US26818M1080
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.